ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones Portfolio News / By Libby Nunan ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones Read More »
Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones Portfolio News / By Libby Nunan Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones Read More »
A2 Biotherapeutics Announces FDA Clearance of IND for A2B543 for Treatment of Adults with Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors that Express Mesothelin and Have Lost HLA-A*02 Expression Portfolio News / By Libby Nunan A2 Biotherapeutics Announces FDA Clearance of IND for A2B543 for Treatment of Adults with Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors that Express Mesothelin and Have Lost HLA-A*02 Expression Read More »
InduPro Therapeutics Announces Strategic Collaboration with Lilly to Develop First-in-Class Bispecific/Multispecific Oncology Therapeutics Using InduPro’s Proximity-Guided Platform Portfolio News / By Libby Nunan InduPro Therapeutics Announces Strategic Collaboration with Lilly to Develop First-in-Class Bispecific/Multispecific Oncology Therapeutics Using InduPro’s Proximity-Guided Platform Read More »
Kallyope Announces 2026 Strategic Priorities for Migraine and Metabolism Portfolio Based on Novel Neural Circuits Platform Portfolio News / By Libby Nunan Kallyope Announces 2026 Strategic Priorities for Migraine and Metabolism Portfolio Based on Novel Neural Circuits Platform Read More »
Remix Therapeutics Appoints Mythili Koneru, MD, PhD, as Chief Medical Officer Portfolio News / By Libby Nunan Remix Therapeutics Appoints Mythili Koneru, MD, PhD, as Chief Medical Officer Read More »
Kenai Therapeutics Receives $8M Grant from California Institute for Regenerative Medicine (CIRM) to Advance RNDP-001 for Treatment of Idiopathic Parkinson’s Disease Portfolio News / By Libby Nunan Kenai Therapeutics Receives $8M Grant from California Institute for Regenerative Medicine (CIRM) to Advance RNDP-001 for Treatment of Idiopathic Parkinson’s Disease Read More »
Atavistik Bio Raises $120 Million Series B Financing to Advance the Development of Selective Allosteric Small Molecule Therapeutics for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT) and Myeloproliferative Neoplasms (MPNs) Portfolio News / By Libby Nunan Atavistik Bio Raises $120 Million Series B Financing to Advance the Development of Selective Allosteric Small Molecule Therapeutics for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT) and Myeloproliferative Neoplasms (MPNs) Read More »
Hexagon Bio Forms Joint Venture with Corteva, Powering Next Generation of Nature Inspired Solutions for Crop Protection Portfolio News / By Libby Nunan Hexagon Bio Forms Joint Venture with Corteva, Powering Next Generation of Nature Inspired Solutions for Crop Protection Read More »
Kenai Therapeutics Announces First Patient Dosed in Phase 1 REPLACE™ Clinical Trial of Neuron Replacement Cell Therapy RNDP-001 for Idiopathic Parkinson’s Disease Portfolio News / By Libby Nunan Kenai Therapeutics Announces First Patient Dosed in Phase 1 REPLACE™ Clinical Trial of Neuron Replacement Cell Therapy RNDP-001 for Idiopathic Parkinson’s Disease Read More »
